Mariner’s BioRestorative Therapies BRTX Stock Holding History

Mariner’s Portfolio BRTX Stock Details BRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-26,831	Closed	-$46.7K	–	3144
2023 Q4	$46.7K	Buy	26,831 +163	+0.6%	+$311	﹤0.01%	2944
2023 Q3	$47.7K	Hold	26,668	–	–	﹤0.01%	2775
2023 Q2	$118K	Hold	26,668	–	–	﹤0.01%	2601
2023 Q1	$91K	Hold	26,668	–	–	﹤0.01%	2588
2022 Q4	$73K	Hold	26,668	–	–	﹤0.01%	2567
2022 Q3	$86K	Buy	+26,668	New	+$82.8K	﹤0.01%	2235

Other funds holding BRTX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Mariner's BRTX Position: Q1 2024 in Review

Mariner sold out of BioRestorative Therapies (BRTX) in Q1 2024, closing a stake of 26,831 shares — an estimated $46.7K sold.

Mariner first reported a position in BRTX in Q3 2022 and held it in 6 quarters. The position peaked at $118K in Q2 2023. 12 funds tracked by Wall St. Rank hold BRTX as of Q1 2024.

Mariner reported no remaining BioRestorative Therapies position as of Q1 2024 after selling out during the quarter.
Mariner sold 26,831 BioRestorative Therapies shares in Q1 2024, an estimated $46.7K.
Mariner first reported a position in BioRestorative Therapies in Q3 2022 and held it in 6 quarters.
Mariner's BioRestorative Therapies position peaked at $118K in Q2 2023.
12 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q1 2024.

Based on Mariner's 13F filing for Q1 2024, filed 15 May 2024.